Skip to main content

izokibep

izokibep: developed by 1 company · 3 clinical trials tracked.

izokibep evidence translation

What we can confirm

3 tracked trials

What it means

Source-backed records connect izokibep to SLRN; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could izokibep → SLRN affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Related indications

Hidradenitis Suppurativa; Psoriatic ArthritisHidradenitis SuppurativaPsoriatic Arthritis

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
ACELYRIN, Inc. (SLRN)
Hidradenitis Suppurativa; Psoriatic Arthritis
Phase 3
Clinical Trials (3)

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT05905783·Phase 3·SLRN
Terminated

Primary endpoint: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 12

InterventionalRandomizeddouble258 targetStarted 2023-06Completion 2025-0150 sites · United StatesACELYRIN Inc.

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis

NCT05623345·Phase 2/Phase 3·SLRN
Terminated

Primary endpoint: Number of Participants Who Achieved 50% Improvement in American College of Rheumatology (ACR50) at Week 16

InterventionalRandomizeddouble351 targetStarted 2022-11Completion 2024-0850 sites · Bulgaria, Canada, Czechia, United StatesACELYRIN Inc.

A Phase 2b Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT05355805·Phase 2·SLRN
Completed

Primary endpoint: Part A: Number of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 12

InterventionalRandomizeddouble205 enrolledStarted 2022-05Completion 2024-0244 sites · Canada, Germany, Hungary, Poland…ACELYRIN Inc.

Frequently asked questions

Who is developing izokibep?

izokibep is being developed by ACELYRIN, Inc..

How many clinical trials involve izokibep?

BioSniper tracks 3 clinical trials involving izokibep.